Targeting a specific RNA to treat blood vessel dysfunction
Development of lesion-targeted lncRNA nanotherapeutic for vascular smooth muscle dysfunction
This study is looking at a way to help people who have thickening of their blood vessels after procedures like angioplasty or stenting, by using a special treatment that delivers a helpful molecule to the affected areas to keep their blood flow healthy.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Arizona State University-Tempe Campus NIH-funded |
| Lab location | 1 site (Tempe, United States) |
| Project ID | NIH-11192960 on NIH RePORTER |
What this research studies
This research focuses on addressing neointimal hyperplasia, a condition that leads to thickening of arterial walls and reduced blood flow after vascular interventions. It investigates the role of a long noncoding RNA, CARMN, which is crucial for the proper function of vascular smooth muscle cells. By developing a targeted nanotherapeutic that delivers CARMN transcripts directly to affected areas, the research aims to restore normal cell function and prevent complications associated with vascular damage. Patients may benefit from improved outcomes in procedures like angioplasty and stenting.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals who have experienced vascular interventions and are at risk for neointimal hyperplasia.
Not a fit: Patients who do not have a history of vascular interventions or those with conditions unrelated to vascular smooth muscle dysfunction may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that significantly improve recovery and outcomes for patients undergoing vascular interventions.
How similar studies have performed: Previous studies have shown promising results with similar approaches targeting RNA for vascular conditions, indicating potential for success in this novel application.
Where this research is happening
Tempe, United States
- Arizona State University-Tempe Campus — Tempe, United States (Active)
Researchers
- Principal investigator: Wang, Mark Kuei-Chun — Arizona State University-Tempe Campus
- Study coordinator: Wang, Mark Kuei-Chun
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.